Medicamen Organics Completes Preferential Allotment of Equity Shares and Convertible Warrants
Medicamen Organics Limited has finalized the allotment of equity shares and convertible warrants on a preferential basis, following approval by its Board of Directors at a meeting held on June 09, 2026. This private placement involved various investors receiving specified securities against cash consideration.The transaction encompassed both promoter and non-promoter allottees. The company confirmed that the receipt of funds toward these allotted securities meets compliance requirements concerning the preferential issue, as verified by independent auditors.
Details regarding the allotment, including the type of security issued and the amount of consideration received, are summarized below:
| Allottee Name | Category | Type of Security Issued | Number of Securities | Amount of Consideration (Rs.) |
|---|---|---|---|---|
| Bal Klshan Gupta | Promoter (Individual) | Convertible Warrants (25% value) | 1,85,715 | 16,25,006.25 |
| Bal Klshan Gupta | Promoter (Individual) | Equity | 7,14,285 | 2,49,99,975 |
| Pradeep Kumar Jain | Non-Promoter (Individual) | Convertible Warrants (75% value) | 10,00,000 | 2,62,50,000 |
| Pradeep Kumar Jain | Non-Promoter (Individual) | Equity | 20,00,000 | 7,00,00,000 |
| Total | Total | Total | 39,00,000 | 12,2B,74,981 |
The allotment included the conversion of a loan into equity shares for one promoter. The consideration was received from allottees' respective bank accounts, as recorded in the company's statements and documents.
Medicamen Organics Limited confirmed compliance with relevant regulations concerning the preferential issue, maintaining records including bank account statements verifying the receipt of the balance consideration from each allottee's bank account.
MEDIORG Stock Price Movement
As of 1:58 PM, shares of Medicamen Organics Limited are shedding 4.76% in live trading, currently at ₹20.00 as the market progresses. The equity has seen a traded volume of 6,000 shares so far today.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.